Contrasting Alkermes (NASDAQ:ALKS) and Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Risk & Volatility

Dyadic International has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Profitability

This table compares Dyadic International and Alkermes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Alkermes	3.96%	4.15%	2.19%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dyadic International and Alkermes, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1	0	2	0	2.33
Alkermes	1	4	12	1	2.72

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 476.70%. Alkermes has a consensus price target of $54.56, indicating a potential upside of 18.36%. Given Dyadic International’s higher possible upside, equities research analysts clearly believe Dyadic International is more favorable than Alkermes.

Earnings and Valuation

This table compares Dyadic International and Alkermes”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09 million	6.13	-$7.36 million	($0.23)	-2.26
Alkermes	$1.48 billion	5.24	$241.66 million	$0.38	121.32

Alkermes has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

27.9% of Dyadic International shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Alkermes beats Dyadic International on 11 of the 15 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.